This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Diabetes Mellitus, Non-Insulin-Dependent or High Risk for Cardiovascular Event
and you are
between 40 and 130
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

Provided treatments

  • Drug: Dapagliflozin 10 mg
  • Drug: Placebo tablet
Tris trial is registered with FDA with number: NCT01730534. The sponsor of the trial is AstraZeneca and it is looking for 17276 volunteers for the current phase.
Official trial title:
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes